GSK, european union and Endometrial Cancer
GSK PLC GSK shares inched down 0.37% to £13.54 Monday, on what proved to be an all-around favorable trading session for the ...
In a deal worth up to $1.15 billion, GSK is acquiring precision medicine biotech IDRx and its phase 3-ready gastrointestinal ...
J&J agreed to buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of reentry into neuroscience by large ...
Shares of GSK PLC GSK advanced 1.58% to £13.49 Thursday, on what proved to be an all-around favorable trading session for the ...
And while Wood said the pharma still isn’t interested in joining the overcrowded obesity landscape, GSK is considering ways ...
The British pharma giant announced plans to acquire IDRx, a Plymouth-based biotech working on precision treatments for ...
GSK’s share price has been pressured recently from several negative events, but this may leave a bargain to be had. I've ...
In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against other undervalued defensive Stocks for 2025. The consumer defensive sector covers products that everyone ...
GSK plc (GSK, GSK.L) announced the European Commission has approved Jemperli in combination with chemotherapy for first-line ...
GSK (NYSE:GSK – Get Free Report) was downgraded by investment analysts at StockNews.com from a “strong-buy” rating to a “buy” ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback